In preclinical models, ABT-263 has demonstrated potent antitumor activity and clinical efficacy in Bcl-2-driven tumors, such as chronic lymphocytic leukemia [11], [13], [21], [43]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.